{
    "ticker": "SBIO",
    "name": "Spring Bank Pharmaceuticals, Inc.",
    "description": "Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to advancing innovative therapies for the treatment of viral infections and cancer. Founded in 2010, the company specializes in the development of a new class of medicines known as small molecule therapeutics that aim to improve patient outcomes through targeted mechanisms of action. One of its leading candidates, SB 9200, is an oral small molecule currently in clinical trials for the treatment of hepatitis B virus (HBV) infection, designed to enhance the immune response against the virus. In addition to SB 9200, Spring Bank is exploring next-generation therapies targeting other viral diseases and cancer, leveraging its proprietary proprietary platforms. The company is dedicated to addressing unmet medical needs and enhancing the lives of patients by delivering effective and safe treatment options. With a strong pipeline of candidates, Spring Bank is positioned to make significant contributions to the fields of virology and oncology, striving to translate scientific innovation into meaningful healthcare outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Newton, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.springbankpharm.com",
    "ceo": "David P. Macdonald",
    "social_media": {
        "twitter": "https://twitter.com/SpringBankPharma",
        "linkedin": "https://www.linkedin.com/company/spring-bank-pharmaceuticals/"
    },
    "investor_relations": "https://www.springbankpharm.com/investors",
    "key_executives": [
        {
            "name": "David P. Macdonald",
            "position": "CEO"
        },
        {
            "name": "Lori A. Glover",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "SB 9200",
                "SB 11285"
            ]
        }
    ],
    "seo": {
        "meta_title": "Spring Bank Pharmaceuticals, Inc. | Innovative Therapeutics for Viral Infections and Cancer",
        "meta_description": "Spring Bank Pharmaceuticals, Inc. is focused on developing innovative small molecule therapies for viral infections and cancer. Learn about their clinical programs and commitment to addressing unmet medical needs.",
        "keywords": [
            "Spring Bank Pharmaceuticals",
            "SB 9200",
            "Viral Infections",
            "Cancer Therapeutics",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Spring Bank Pharmaceuticals known for?",
            "answer": "Spring Bank Pharmaceuticals is known for developing innovative small molecule therapeutics for the treatment of viral infections and cancer."
        },
        {
            "question": "Who is the CEO of Spring Bank Pharmaceuticals?",
            "answer": "David P. Macdonald is the CEO of Spring Bank Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Spring Bank Pharmaceuticals headquartered?",
            "answer": "Spring Bank Pharmaceuticals is headquartered in Newton, Massachusetts, USA."
        },
        {
            "question": "What are Spring Bank's main therapeutic candidates?",
            "answer": "Spring Bank's main therapeutic candidates include SB 9200 and SB 11285."
        },
        {
            "question": "When was Spring Bank Pharmaceuticals founded?",
            "answer": "Spring Bank Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "GILD",
        "BMY",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "JNJ",
        "PFE"
    ]
}